NASDAQ:TBPH - Theravance Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.43
  • Forecasted Upside: 93.56 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$17.27
▲ +0.7 (4.22%)
1 month | 3 months | 12 months
Get New Theravance Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TBPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TBPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$33.43
▲ +93.56% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Theravance Biopharma in the last 3 months. The average price target is $33.43, with a high forecast of $42.00 and a low forecast of $29.00. The average price target represents a 93.56% upside from the last price of $17.27.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Theravance Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00Low
i
2/24/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$35.00 ➝ $41.00High
i
12/16/2020Morgan StanleyLower Price TargetOverweight$32.00 ➝ $31.00Low
i
11/23/2020Evercore ISIReiterated RatingOutperform$30.00Medium
i
11/6/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by D. Tsao at HC Wainwright
11/6/2020SVB LeerinkLower Price TargetOutperform$40.00 ➝ $35.00High
i
10/14/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$32.00High
i
Rating by Vikram Purohit at Morgan Stanley
8/10/2020Morgan StanleyLower Price TargetEqual Weight$30.00 ➝ $29.00Low
i
Rating by Vikram Purohit at Morgan Stanley
8/7/2020Piper SandlerLower Price TargetOverweight$35.00 ➝ $30.00Low
i
7/7/2020JPMorgan Chase & Co.Initiated CoverageOverweight$29.00High
i
6/15/2020Morgan StanleyInitiated CoverageEqual Weight$30.00High
i
5/13/2020CowenInitiated CoverageOutperform$42.00High
i
5/7/2020HC WainwrightReiterated RatingBuy$32.00High
i
Rating by Douglas Tsao at HC Wainwright
4/23/2020HC WainwrightReiterated RatingBuy$32.00Low
i
Rating by Douglas Tsao at HC Wainwright
2/25/2020HC WainwrightBoost Price TargetBuy$30.00 ➝ $32.00Medium
i
Rating by D. Tsao at HC Wainwright
2/25/2020Piper SandlerLower Price TargetOverweight$40.00 ➝ $35.00High
i
1/8/2020HC WainwrightBoost Price TargetBuy$25.00 ➝ $30.00High
i
Rating by D. Tsao at HC Wainwright
11/6/2019Piper Jaffray CompaniesLower Price TargetOverweight$55.00 ➝ $40.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
11/6/2019Robert W. BairdUpgradeUnderperform ➝ Neutral$22.00 ➝ $18.00Low
i
10/29/2019HC WainwrightInitiated CoverageBuy$25.00Low
i
Rating by D. Tsao at HC Wainwright
9/9/2019Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Tyler Van Buren at Piper Jaffray Companies
8/16/2019Cantor FitzgeraldSet Price TargetBuy$55.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
7/31/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00N/A
i
Rating by Tyler Van Buren at Piper Jaffray Companies
6/19/2019Piper Jaffray CompaniesReiterated RatingPositive$55.00Medium
i
4/12/2019Cantor FitzgeraldReiterated RatingBuy$55.00Low
i
3/28/2019Cantor FitzgeraldReiterated RatingBuy$55.00Low
i
2/26/2019Cantor FitzgeraldReiterated RatingBuy$55.00Low
i
1/28/2019Cantor FitzgeraldInitiated CoverageBuy$55.00High
i
Rating by Louise Chen at Cantor Fitzgerald
11/9/2018Cantor FitzgeraldReiterated RatingBuy$55.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
11/7/2018SVB LeerinkSet Price TargetBuy$38.00Medium
i
Rating by Geoff Porges at SVB Leerink LLC
10/23/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
i
Rating by Tyler Van Buren at Piper Jaffray Companies
10/22/2018Cantor FitzgeraldReiterated RatingBuy$55.00High
i
Rating by Louise Chen at Cantor Fitzgerald
8/1/2018Piper Jaffray CompaniesReiterated RatingOverweight$55.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
8/1/2018Cantor FitzgeraldSet Price TargetBuy$55.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/1/2018Needham & Company LLCReiterated RatingBuy$40.00Low
i
Rating by Alan Carr at Needham & Company LLC
5/24/2018Cantor FitzgeraldSet Price TargetBuy$55.00Medium
i
Rating by Louise Chen at Cantor Fitzgerald
5/9/2018Needham & Company LLCReiterated RatingBuy$40.00Low
i
5/9/2018SVB LeerinkSet Price TargetBuy$41.00 ➝ $31.00High
i
5/8/2018Cantor FitzgeraldSet Price TargetBuy$55.00High
i
Rating by Louise Chen at Cantor Fitzgerald
3/29/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$45.00Medium
i
2/27/2018Cantor FitzgeraldSet Price TargetBuy$55.00High
i
Rating by Louise Chen at Cantor Fitzgerald
2/8/2018SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $48.00Medium
i
12/5/2017Needham & Company LLCReiterated RatingBuyHigh
i
11/7/2017Cantor FitzgeraldReiterated RatingBuy$55.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/A
i
10/25/2017Cantor FitzgeraldSet Price TargetBuy$55.00N/A
i
Rating by Louise Chen at Cantor Fitzgerald
9/26/2017Cantor FitzgeraldReiterated RatingBuy$55.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
9/19/2017Cantor FitzgeraldReiterated RatingBuy$55.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$45.00Medium
i
8/16/2017Cantor FitzgeraldSet Price TargetBuy$55.00Low
i
Rating by Louise Chen at Cantor Fitzgerald
8/2/2017Needham & Company LLCReiterated RatingBuyHigh
i
7/19/2017Cantor FitzgeraldSet Price TargetBuy$55.00High
i
Rating by Louise Chen at Cantor Fitzgerald
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$55.00High
i
5/11/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.00Low
i
5/10/2017SVB LeerinkSet Price TargetBuy$47.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$42.00Medium
i
2/28/2017Needham & Company LLCReiterated RatingBuy$40.00N/A
i
12/21/2016Needham & Company LLCInitiated CoverageBuy$40.00N/A
i
11/9/2016SVB LeerinkReiterated RatingBuy$33.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
11/3/2016Piper Jaffray CompaniesInitiated CoverageOverweight$42.00N/A
i
10/31/2016SVB LeerinkReiterated RatingOutperform$35.00 ➝ $33.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
10/21/2016SVB LeerinkSet Price TargetBuy$35.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
10/12/2016Robert W. BairdDowngradeNeutral ➝ Underperform$19.00 ➝ $24.00N/A
i
9/19/2016GuggenheimReiterated RatingPositive$40.00N/A
i
Rating by Louise Chen at Guggenheim
8/29/2016Evercore ISIInitiated CoverageBuy$41.00N/A
i
8/9/2016SVB LeerinkReiterated RatingBuy$31.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
8/3/2016Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
i
6/20/2016SVB LeerinkBoost Price TargetOutperform$29.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/20/2016GuggenheimInitiated CoverageBuy$30.00N/A
i
6/10/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Paul Matteis at SVB Leerink LLC
6/4/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/12/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by P. Matteis at SVB Leerink LLC
5/12/2016SVB LeerinkInitiated CoverageOutperform$26.00N/A
i
5/7/2016Bank of AmericaDowngradeBuy ➝ NeutralN/A
i
5/5/2016Bank of AmericaDowngradeBuy ➝ NeutralN/A
i
(Data available from 3/1/2016 forward)
Theravance Biopharma logo
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Read More

Today's Range

Now: $17.27
$16.76
$17.40

50 Day Range

MA: $18.61
$16.75
$20.64

52 Week Range

Now: $17.27
$14.48
$31.35

Volume

4,770 shs

Average Volume

358,979 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Theravance Biopharma?

The following Wall Street research analysts have issued research reports on Theravance Biopharma in the last twelve months: Cowen Inc, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for TBPH.

What is the current price target for Theravance Biopharma?

7 Wall Street analysts have set twelve-month price targets for Theravance Biopharma in the last year. Their average twelve-month price target is $33.43, suggesting a possible upside of 93.6%. Cowen Inc has the highest price target set, predicting TBPH will reach $42.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $29.00 for Theravance Biopharma in the next year.
View the latest price targets for TBPH.

What is the current consensus analyst rating for Theravance Biopharma?

Theravance Biopharma currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TBPH will outperform the market and that investors should add to their positions of Theravance Biopharma.
View the latest ratings for TBPH.

What other companies compete with Theravance Biopharma?

How do I contact Theravance Biopharma's investor relations team?

Theravance Biopharma's physical mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company's listed phone number is 650-808-6000 and its investor relations email address is [email protected] The official website for Theravance Biopharma is www.theravance.com.